News & Events

May 15, 2012 --

Dr. Joe Guiles to present poster on peptide-drug conjugate manufacturing conisderations at TIDES meeting

October 6, 2011 --

Cedarburg Hauser Pharmaceuticals Named Top 10 Standout CMO by FiercePharma Manufacturing

August 3, 2011 --

Dr. Joseph Guiles Named General Manager of INB Hauser Pharmaceutical Services

February 16-19, 2010 --

Cedarburg Hauser Pharmaceuticals attends Informex, San Francisco, CA

March 17, 2009 --

Cedarburg Pharmaceuticals acquires Hauser Pharmaceutical Services

Dr. Joe Guiles to present poster on peptide-drug conjugate manufacturing considerations at TIDES Meeting

Dr. Joe Guiles, Vice President and General Manager at Cedarburg Hauser Pharmaceuticals, will be presenting a poster titled “Current Peptide-Drug Conjugates & Early Stage Manufacturing Considerations” at TIDES: Oligonucleotide & Peptide Research, Technology & Product Development, held in Las Vegas, NV, May 20-23. This is the latest in a series of informational pieces that Cedarburg Hauser has developed on peptide-drug conjugates.

In addition to the TIDES poster, Cedarburg Hauser has published an article in the May issue of Specialty Chemical Magazine on the topic. The article, titled “Peptide-drug conjugates: Types, utility & manufacturing” looks at the composition, chemical assembly and manufacturing challenges of these exciting pharmaceuticals.

Peptide-drug conjugate resources available from Cedarburg Hauser Pharmaceuticals:

TIDES Poster

Current Peptide-Drug Conjugates & Early Stage Manufacturing 

Specialty Chemical Magazine Article

Peptide-drug conjugates: Types, utility & manufacturing 

Case Studies

Peptide Conjugate with Potent Therapeutic Agent 

Anti-Cancer Peptide Conjugate

October 6, 2011:

Cedarburg Hauser Pharmaceuticals Named Top 10 CMO by FiercePharma Manufacturing

1. Process optimization
2. Lyophilization
3. Fill/finish
4. Packaging
5. Stability, storage and testing

Back to Top

August 3, 2011:

Dr. Joseph Guiles Named General Manager of INB Hauser Pharmaceutical Services

Cedarburg Hauser Pharmaceuticals has continued to strengthen its senior management by adding Joseph Guiles, PhD as the new General Manager of INB Hauser Pharmaceutical Services located in Denver, Colorado.

“Our mission is to be a trusted supplier and valuable advisor to our clients in the areas of early stage drug/API development and manufacturing,” said Tony Laughrey, President & CEO of Cedarburg Hauser Pharmaceuticals.  “In order to meet the diverse needs of our clients it is vitally important that we have senior leadership that not only understands what is important to all sizes of pharmaceutical companies, but have also walked in their shoes.”

With the addition of Dr. Guiles, Cedarburg Hauser has done exactly that.  He has been very successful throughout his career in big pharma, medium pharma and small/start-up pharmaceutical companies.  Dr. Guiles is an accomplished medicinal chemist having designed three separate agents that have entered human clinical study.  He has been involved in driving several products to IND and NDA development stage and he truly understands what Cedarburg Hauser’s clients are up against at every stage of their compound’s development.

“Dr. Guiles has been in our client’s position and therefore understands what they need from their development and manufacturing partners,” said Chuck Boland, Executive Vice President of Cedarburg Hauser, “and that will help us continue to provide the services they need to be successful.”

“By adding Dr. Guiles to our leadership group, we have continued to strengthen our ability to provide our clients with the valuable perspective and advice they often need before, during and after a development project.  We can help them avoid the potential landmines that can often come up during a project and potentially save them time and money,” said Mark Millar, Director of Project Management at Cedarburg Hauser.  

Joseph Guiles, PhD, is a 20 year bioscience veteran in which 18 years were spent in private sector pharmaceutical or biotech startups both in Colorado and New Jersey. His past employers include Sanofi-Aventis, Johnson & Johnson, Sterling-Winthrop and Replidyne.  He has directed pharmaceutical R&D, QC, manufacturing and supply chain management operations.

Joe comes to Cedarburg Hauser Pharmaceuticals from MicroRX at CSU Ventures in Fort Collins, Colorado where he was the Executive Director and co-founded two bioscience startup companies. He also co-founded the Colorado Center for Drug Discovery (C2D2), a new initiative to enhance drug discovery capability in Colorado’s public sector.

Joe earned his PhD in chemistry at Colorado State University.  His expertise as a organic chemist has been recognized with 25 published research papers, has given numerous seminars and lectures, and has 12 issued patents.

Back to Top

February 16-19, 2010:

Cedarburg Hauser Pharmaceuticals Attends Informex, San Francisco, CA

As the premier networking event for the chemical industry in the United States, Informex is designed to showcase the chemistry capabilities of high-value, high-quality businesses. Companies that invest in R&D, quality systems, applications development and more. Please visit us at booth #1820 (www.informex.com).

Back to Top

March 17, 2009

CEDARBURG PHARMACEUTICALS ACQUIRES HAUSER PHARMACEUTICAL SERVICES

Acquisition creates a leader in Contract Development and Manufacturing

Grafton, WI. (March 17, 2009) – Cedarburg Pharmaceuticals, Inc. (“Cedarburg”) -- a privately owned chemistry-based Contract Development Manufacturing Organization (“CDMO”) specializing in the production of Active Pharmaceutical Ingredients (API’s) and key intermediates for the pharmaceutical and biopharmaceutical industries announced today its acquisition of InB: Hauser Pharmaceutical Services (“Hauser”). The acquisition further strengthens Cedarburg’s position as a leader in the rapidly growing CDMO market and leverages the trusted reputation and synergistic capabilities of both companies to offer clients a more fully-integrated manufacturing platform strategically focused on helping client’s move new chemical entities (NCE’s) to market.

Hauser’s expertise in natural products, isolation/ purification and cGMP manufacturing augment Cedarburg’s synthetic chemistry and cGMP manufacturing expertise and effectively broadens the overall service capabilities offered to clients. The acquisition expands Cedarburg’s extensive inventory of unit operations and comprehensive analytical instrumentation to include NMR and MALS and further amplifies Cedarburg’s toll manufacturing capabilities for the production of API’s and key intermediates.

The newly formed company doing business as Cedarburg Hauser Pharmaceuticals, will offer customers a broad range of best-in-class pharmaceutical services to meet the development and production needs of its clients. Both companies offer a combined 34-year history working in the pharmaceutical industry, proven turn-key cGMP compliance systems, and seasoned professionals specialized in providing highly customized process and analytical chemistry from the bench through commercial production.

With over 70,000 + square feet of multi-purpose US-based FDA-registered facilities (process development laboratories, kilo and commercial scale manufacturing suites, analytical and microbiology laboratories, stability and material sample storage) the combined operations will focus on the following specialty areas: Highly customized NCE’s requiring complex chemistry, Cytotoxic & Potent API’s, Naturally Derived & Semi-Synthetic API’s, Controlled Substances, Commercial cGMP API manufacturing, and High-Value Dietary Supplements and Cosmetics (ACI’s).

“The acquisition allows us to maximize the true potential of both organizations as one fully integrated contract development and manufacturing organization building value for our shareholders, employees, and customers. The merger will also speed up the development and manufacturing of products currently in our product pipeline.” said R. Anthony (Tony) Laughrey, President and CEO of Cedarburg. “The new Cedarburg Hauser is well positioned to provide increased efficiency for our clients as they move their critical process development and manufacturing projects through clinical development and ultimately into the commercial arena" Mr. Laughrey continued.

About Cedarburg Pharmaceuticals
Cedarburg Pharmaceuticals is a value-driven commercial and clinical API provider. We define value as making life simpler for our customers. That means understanding our customers' needs and exceeding their expectations through transparent project management and resourcefully applying our expertise in process development, validation, Scale-Up and analytical method development. Backed by full cGMP compliance and QA oversight, our experience and flexibility enable us to succeed where others fail.

About InB: Hauser Pharmaceutical Services
Hauser is a contract development manufacturing organization (CDMO) dedicated to providing excellent service, high-quality actives and key intermediates to the pharmaceutical and biopharmaceutical industries. Hauser offers an established, completely integrated platform proven to quickly and efficiently move our client’s products to market. Over the last 25-years Hauser has actively developed, scaled and optimized hundreds of unique chemical processes and analytical methods for our clients, starting from the pre-clinical stage to commercial production (mg –to-multi-hundred kilos) under strict cGMP guidelines, in our US-based facilities. Hauser’s specialties include cytotoxics, next-generation chemotherapeutics, multi-step custom synthesis, naturally derived actives, and complex separation projects.

Back to Top